Early Phase 1 N=15 Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat
Adiposity
Primary: Number of Participants With Adverse Events — 08; 01; 02 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=9 Autologous CD4 T-Cells in HIV (C34-CXCR4)
Hiv
Primary: The Number of Subjects With Treatment Related Adverse Events — 2; 1; 2 Participants
Early Phase 1 N=19 CRF - Nociceptin Receptor Interactions
Healthy
Primary: [C-11]NOP-1A Volume of Distribution Expressed Relative to Total Plasma Concentration — 16.3; 18.7; 11.6; 13.3 mL/cm^3 — p=0.005
Early Phase 1 N=11 Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study
Pulmonary Disease, Chronic Obstructive · E-cigarettes
Primary: Pulmonary Microvascular Blood Flow (PMBF), Measured on Gadolinium-enhanced MRI, Between E-cigarette Exposed and Unexposed Conditions — 74.4; 63.1 mL(blood)/min/mL(lung)…
Early Phase 1 N=38 Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States
Healthy
Primary: AUC — 4.78; 15.00; 5.41; 16.34 uM hr/L
Early Phase 1 N=99 Hollings Cancer Center Varenicline Sampling Study
Smoking · Smoking Cessation · Smoking, Tobacco
Primary: Quit Attempts — 30; 24; 26; 17 Participants
Early Phase 1 N=20 Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients
Systemic Sclerosis
Primary: Raynaud's Condition Scale — 5; 5; 6.5; 3 score on a scale — p=0.256
Early Phase 1 N=36 Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects
Alzheimer Disease
Primary: Brain Flortaucipir Uptake — 1.780; 1.317; 1.128; 1.107 standardized uptake value ratio (SUVr)
Early Phase 1 N=28 Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama
Toxic Effect of Other Corrosive Organic Compounds
Primary: Percent Change From Baseline for Total PCB Levels — 92; 96 % of baseline total PCBs
Early Phase 1 N=71 Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075
Opioid Use Disorder
Primary: Recruitment Rate — 76; NA; NA; 71 Participants
Early Phase 1 N=26 iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.
Patients With Post Orthotopic Heart Transplantation Status
Primary: To Measure Free Fatty Acid by Imaging Patients With Increased Levels of iNOS Using [18F](+/-)NOS.
Early Phase 1 N=103 Leptin Infusion and Endothelial Vasomotor Response
Endothelial Dysfunction · Obesity · Vasodilation
Primary: Forearm Blood-flow (FBF) — 1.75; 3.1; NA; NA ml/100 mg tissue/min
Early Phase 1 N=39 A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Gynecologic Neoplasms · Epithelial Ovarian Cancer · Uterine Endometrial Cancer
Primary: Change in Tumor Immune Infiltrates as Measured by PD-L1 Modified H-Score — 13.2 score on a scale
Early Phase 1 N=14 PK and DPK of Lidocaine Dermal Products
Heat Effect
Primary: Measurement of Maximum Serum Concentration (Cmax) — 306.8; 214.9; 390.76; 286.49 ng/mL
Early Phase 1 N=9 Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
Fatty Liver
Primary: Hepatic Fatty Acid Oxidation